Testing a Dendritic Cell Vaccine With Pembrolizumab for Breast Cancer That Has Spread to the Brain
Original title: Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage study, so the treatment is still being tested in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing whether two immune treatments, given together, can help people whose breast cancer has spread to the brain.
Who this trial is for. This trial is for people with triple negative breast cancer or HER2+ breast cancer that has spread to the brain. It tests a dendritic cell vaccine aimed at Her2/Her3 along with a drug called pembrolizumab. Both work by helping the immune system find and attack cancer cells.
Where it stands. This trial has not reported results. It is looking at how well the vaccine and pembrolizumab work together in people with brain metastasis from these types of breast cancer. The answer is not in yet.
What this means, and what it doesn't
What it could mean: The researchers think this combination may shrink the cancer, but that is what the trial is set up to find out. If your cancer matches what this trial is studying, you could ask your care team whether a trial like this is worth looking into.
What it doesn't mean: This does not mean the treatment works. A trial is a test, not a proven treatment. Joining one is not a guarantee that you will benefit, and it is not a promise of a cure. Only the trial team can decide who can take part.
Source: ClinicalTrials.gov, July 21, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.